This means: It is not FDA-approved for human use outside of clinical trials It cannot be sold for dietary or medical use only for research purposes Possessing or using it without a prescription is technically legal in personal research contexts but may violate athletic federation or workplace testing rules Drug Testing Considerations CJC1295 and its metabolites can be detected in anti-doping tests and are listed on the World Anti-Doping Agency (WADA) Prohibited List under Peptide Hormones, Growth Factors, and Related Substances
Although not approved for weight loss, many patients began taking Ozempic off-label to lose weight, making it one of the most talked-about drugs in the growing market for semaglutide weight loss drugs
Notably, affective blunting has been reported as a side effect of other commonly prescribed medications, including SSRIs and beta blockers (MacCormack et al., 2021
Clinical trials show Contrave produces modest weight loss (510% body weight in responders over 56 weeks), with effects primarily through central nervous system modulation rather than slowed gastric emptying or incretin hormone stimulation
SURPASS-2 results (40 weeks, type 2 diabetes): Tirzepatide 5 mg: -7.6 kg weight loss, -2.01% HbA1c reduction Tirzepatide 10 mg: -9.3 kg weight loss, -2.24% HbA1c reduction Tirzepatide 15 mg: -11.2 kg weight loss, -2.30% HbA1c reduction Semaglutide 1 mg: -5.7 kg weight loss, -1.86% HbA1c reduction SURMOUNT-5 results (72 weeks, obesity): Tirzepatide demonstrated statistically superior weight loss compared to semaglutide 2.4 mg